BEAM · Company research

Beam Therapeutics Inc.

3 upcoming catalysts · 0 phase 2+ trials on file

View Stock opens Yahoo Finance. Prices and performance charts are provided there.

Upcoming catalysts

Trial resultsBEAMBeamH2 2026

Beam expects to report results from its Phase 1/2 study of Risto-cel (BEAM-101) for Sickle cell disease in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.

More details

Entry

Updated BEACON Phase 1/2 data for risto-cel by year-end 2026 · Clinical trial results (readout / topline data)

Drug

Risto-cel (BEAM-101)

For

Sickle cell disease

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

H2 2026 · the company gave a window, not a day

Source note

Company guidance: 'expects to report updated data for the BEACON trial by year-end 2026.' Dosing complete in all adult and adolescent patients.

Checked

Checked by a person when it was added

Verify it

Source: globenewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
BEAM headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBEAMBeamH2 2026

Beam expects to report results from its Phase 1/2 study of BEAM-301 for Glycogen storage disease type Ia (R83C) in the second half of 2026 (no exact date yet). Phase 1/2 is an early study that checks safety and takes a first look at effect.

More details

Entry

BEAM-301 initial clinical data in glycogen storage disease type Ia · Clinical trial results (readout / topline data)

Drug

BEAM-301

For

Glycogen storage disease type Ia (R83C)

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

H2 2026 · the company gave a window, not a day

Source note

Company guides initial clinical data 'in 2026'; only H2 2026 remains, hence the H2 tag.

Checked

Checked by a person when it was added

Verify it

Source: globenewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
BEAM headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneBEAMBeamQ4 2026

Risto-cel (BEAM-101) BLA submission in sickle cell disease, as early as year-end 2026, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Beam (Risto-cel (BEAM-101) for Sickle cell disease): a step in the program rather than a decision or a data readout.

More details

Entry

Risto-cel (BEAM-101) BLA submission in sickle cell disease, as early as year-end 2026 · Company milestone

Drug

Risto-cel (BEAM-101)

For

Sickle cell disease

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

Q4 2026 · the company gave a window, not a day

Source note

Company guidance: 'submit a biologics license application (BLA) for risto-cel as early as year-end 2026' (timing could slip into early 2027).

Checked

Checked by a person when it was added

Verify it

Source: globenewswire.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
BEAM headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Past catalysts

ConferenceBEAMBeamSep 8, 2026

Beam presented data on BEAM-302 for Alpha-1 antitrypsin deficiency at a medical meeting on Sep 8, 2026. The linked source has the details.

More details

Entry

BEAM-302 AATD late-breaking oral at ERS 2026 on Sept 8 · Data presented at a medical meeting

Drug

BEAM-302

For

Alpha-1 antitrypsin deficiency

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

Sep 8, 2026

Source note

Existing item is dated 2026-09; Beam's July 23, 2026 release gives the exact slot (late-breaking oral Sept 8, 2026, 9:30–10:45 CEST, Barcelona) plus an investor webcast the same day at 7:00 a.m. ET. First patient in the global pivotal cohort was dosed July 2026.

Checked

Checked by a person when it was added

Verify it

Source: investingnews.com ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
BEAM headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

ConferenceBEAMBeamMay 18, 2026

Beam presented data on BEAM-302 for Alpha-1 antitrypsin deficiency (AATD) at a medical meeting on May 18, 2026. The linked source has the details.

More details

Entry

BEAM-302 AATD Phase 1/2 topline data presented at ATS 2026 · Data presented at a medical meeting

Drug

BEAM-302

For

Alpha-1 antitrypsin deficiency (AATD)

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

May 18, 2026

Source note

Beam's CMO presented the recently reported BEAM-302 Phase 1/2 data in AATD at the American Thoracic Society International Conference in Orlando, covering 29 treated patients including safety, durability and reduced neutrophil elastase activity.

Checked

Checked by a person when it was added

Verify it

Source: stocktitan.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
BEAM headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

MilestoneBEAMBeamApr 1, 2026

BEACON Phase 1/2 risto-cel sickle cell data published in NEJM, on Apr 1, 2026. A company milestone for Beam (risto-cel (ristoglogene autogetemcel, BEAM-101) for Sickle cell disease with severe VOCs): a step in the program rather than a decision or a data readout.

More details

Entry

BEACON Phase 1/2 risto-cel sickle cell data published in NEJM · Company milestone

Drug

risto-cel (ristoglogene autogetemcel, BEAM-101)

For

Sickle cell disease with severe VOCs

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

Apr 1, 2026

Source note

Interim data from the Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel, formerly BEAM-101) in sickle cell disease with severe vaso-occlusive crises were published in The New England Journal of Medicine.

Checked

Checked by a person when it was added

Verify it

Source: stocktitan.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
BEAM headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Trial resultsBEAMBeamMar 25, 2026

Beam reported results from its Phase 1/2 study of BEAM-302 for Alpha-1 antitrypsin deficiency (AATD) on Mar 25, 2026. The study met its main goal.

More details

Entry

BEAM-302 Phase 1/2 update in AATD; 60 mg selected for pivotal development · Clinical trial results (readout / topline data)

Drug

BEAM-302

For

Alpha-1 antitrypsin deficiency (AATD)

Stage

Phase 1/2 · an early study that checks safety and takes a first look at effect

When

Mar 25, 2026

Source note

Beam reported updated safety and efficacy data from the ongoing Phase 1/2 trial of BEAM-302 in alpha-1 antitrypsin deficiency and selected 60 mg as the optimal biological dose to advance into pivotal development supporting potential accelerated approval.

Checked

Checked by a person when it was added

Verify it

Source: stocktitan.net ↗ — where this entry was taken from
SEC filings (8-K) ↗ — press releases are attached to 8-K filings
ClinicalTrials.gov ↗ — trials of this drug
BEAM headlines on this site

Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page

Things of Interest

Explore reported politician transactions and public investor statements connected to BEAM.

View source-linked activity ↗

Pipeline trials

ClinicalTrials.gov · phase 2 and later

No phase 2+ trials cached for this company.

Company news

No recent headlines on file.